Reported Saturday, Lilly Presents Eloralintide Phase 2 Exit Interview Results, With 74% Reporting Fewer Cravings, 52% Less Food Noise, Alongside EloraTZP, Retatrutide, Zepbound And Foundayo Data At ObesityWeek 2026
Benzinga Newsdesk 1 day ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetesResults from
- Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes
- Results from TRIUMPH-1, TRIUMPH-2 and TRIUMPH-4 demonstrated retatrutide, an investigational triple agonist, reduced obstructive sleep apnea severity and knee osteoarthritis pain in adults with obesity
- People reported Foundayo was simple and easy to use in a new real-world evidence study, while patient-reported outcomes showed that participants treated with eloralintide reported reductions in food noise, food cravings and alcohol consumption
